Commercial Insight: Cytotoxic Therapies - Market growth will slow due to increasing genericization

Table of Contents

EXECUTIVE SUMMARY

• Strategic scoping and focus
• Datamonitor insight into the cytotoxic therapies market
• Related reports
• Upcoming related reports

MARKET DEFINITION

• Market definition for this report
  • Cytotoxic therapies by ATC class

MARKET OVERVIEW

• Seven major markets
  • Current and future market overview
  • Opportunities and threats
• US
  • Current and future market assessment
  • Opportunities and threats
• Japan
  • Current and future market assessment
  • Opportunities and threats
• Five major European markets (5EU)
  • Current and future market assessment
  • Opportunities and threats
• France
  • Current and future market assessment
  • Germany
  • Current and future market assessment
• Italy
  • Current and future market assessment
• Spain
  • Current and future market assessment
• UK
  • Current and future market assessment
• Rest of the world snapshot
  • Current market assessment
  • Opportunities and threats

BRAND DYNAMICS

• Overview of competitive landscape
  • Taxotere and Eloxatin will be in the top 3 cytotoxic brands in 2008 and 2018
• Drivers of brand choice
  • Efficacy and toxicity of a drug are the most important drivers of cytotoxic brand choice
• Trends in marketing strategies
  • Marketing strategy for leading brands
• Leading cytotoxic brands
  • Taxotere (docetaxel; Sanofi-Aventis)
  • Eloxatin (oxaliplatin; Sanofi-Aventis)
  • Gemzar (gemcitabine; Eli Lilly)
  • Dacogen (decitabine; Eisai/Johnson & Johnson)

KEY DEVELOPERS

• Strategic overview
• Trends in corporate strategy
  • Approval in multiple tumor types is most likely to result in significant sales
  • A mature and heavily genericized market means that the experience of large pharmaceutical companies is crucial
  • The current pipeline is relatively small and contains several reformulations of leading cytotoxic brands
• Sanofi-Aventis
  • Corporate strategy
  • Oncology cytotoxics portfolio assessment
• Eli Lilly
  • Corporate strategy
  • Oncology cytotoxics portfolio assessment
• Portfolio assessment of other leading companies

CASE STUDIES

• Introduction
• Case study
  • Supergeneric cytotoxics...not so super?

BIBLIOGRAPHY

• Journal papers
• Websites
• Datamonitor reports
• Other

APPENDIX A - MARKET ASSUMPTIONS

• New product launches
• Patent expiries
• Rest of class definition
• Data definitions, limitations and assumptions
  • Standard units
  • Japanese market data
  • Rest of the World
  • Derivation of sales forecasts and pricing trends
• Forecast methodology
• Report methodology

APPENDIX B

TABLES

• Table: Definition of the cytotoxic therapies market, 2009
• Table: Sales and growth of cytotoxic therapy drug classes in the seven major markets, 2008 - 2018
• Table: Key events impacting the cytotoxic therapies market, 2008 - 2018
• Table: Cytotoxic therapy sales forecasts in the seven major markets ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the cytotoxics market across the seven major markets, 2009 - 2018
• Table: Sales and growth of cytotoxic therapy drug classes in the US, 2008 - 2018
• Table: Top 5 branded cytotoxics in the US in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in the US ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the cytotoxics market in the US, 2009 - 2018
• Table: Sales and growth of cytotoxic therapy drug classes in Japan, 2008 - 2018
• Table: Top 5 branded cytotoxics in Japan in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in Japan ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the cytotoxics market in Japan, 2009
• Table: Sales and growth of cytotoxic therapy drug classes in the five major European markets, 2008 - 2018
• Table: Top 5 branded cytotoxics in the five major European markets in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in the five major European markets ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the cytotoxics market in the five major European markets, 2009
• Table: Top 5 branded cytotoxics in France in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in France ($m), 2008 - 2018
• Table: Top 5 branded cytotoxics in Germany in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in Germany ($m), 2008 - 2018
• Table: Top 5 branded cytotoxics in Italy in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in Italy ($m), 2008 - 2018
• Table: Top 5 branded cytotoxics in Spain in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in Spain ($m), 2008 - 2018
• Table: Top 5 branded cytotoxics in the UK in 2008 and 2018
• Table: Cytotoxic therapy sales forecasts in the UK ($m), 2008 - 2018
• Table: Comparison of cytotoxic drug class sales ($m) in the seven major markets and Rest of the World, 2008
• Table: Comparison of cytotoxic drug class sales ($m) in the BRIC countries, Australia and Canada, 2008
• Table: Leading branded cytotoxic drug sales in the seven major markets ($m), 2008 - 2018
• Table: Marketing strategies employed by the companies behind the top three cytotoxic brands, 2009
• Table: Taxotere - drug profile, 2009
• Table: Impacting factors on the revenues of Taxotere, 2008 - 2018
• Table: Eloxatin - drug profile, 2009
• Table: Impacting factors on the revenues of Eloxatin, 2008 - 2018
• Table: Gemzar - drug profile, 2009
• Table: Impacting factors on the revenues of Gemzar, 2008 - 2018
• Table: Dacogen - drug profile, 2009
• Table: Ongoing Phase III trial investigating Dacogen in acute myeloid leukemia
• Table: Impacting factors on the revenues of Dacogen, 2008 - 2018
• Table: Leading companies in the seven major market cytotoxic therapies market, 2008 - 2018
• Table: Late-phase cytotoxics pipeline, 2009
• Table: Assessment of Sanofi-Aventis' s cytotoxics portfolio, 2009
• Table: Assessment of Eli Lilly' s cytotoxics portfolio, 2009
• Table: Assessment of Pfizer' s cytotoxics portfolio, 2009
• Table: Assessment of Bristol-Myer Squibb' s cytotoxics portfolio, 2009
• Table: Assessment of Roche' s cytotoxics portfolio, 2009
• Table: FDA approvals for Taxol, 1992 - 99
• Table: Historical global sales of Taxol ($m), 1994 - 2008
• Table: Approved and investigational paclitaxel reformulations, 2009
• Table: Historical global sales of Abraxane ($m), 2005 - 08
• Table: Regional launch dates for new cytotoxics in the seven major markets, 2008 - 2018
• Table: Patent expiry dates for the approved cytotoxics in the seven major pharmaceutical markets, 2008 - 2018

FIGURES

• Figure: Cytotoxic therapy sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) by drug class in the seven major markets, 2008 - 2018
• Figure: Performance of leading cytotoxic therapy brands in the seven major markets, 2008 versus 2018
• Figure: Seven major market population aged 60 and over, 2000 - 2050
• Figure: Global therapy sales ($m), 2007 - 2012
• Figure: Cytotoxic therapy sales ($m) in the US, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) in Japan, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) in the five major European markets, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) in France, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) in Germany, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) in Italy, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) in Spain, 2008 - 2018
• Figure: Cytotoxic therapy sales ($m) in the UK, 2008 - 2018
• Figure: Rest of world versus seven major market sales split in the cytotoxic therapies market ($m), 2008
• Figure: Drivers of brand choice for cytotoxic therapy in cancer
• Figure: Taxotere SWOT analysis, 2009
• Figure: Taxotere forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Eloxatin SWOT analysis, 2009
• Figure: Eloxatin forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Gemzar SWOT analysis, 2009
• Figure: Gemzar forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Phase III study of Dacogen versus supportive care in patients with myelodysplastic syndrome
• Figure: Dacogen SWOT analysis, 2009
• Figure: Dacogen forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Historical global sales of Taxol ($m), 1994 - 2008